Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Hyatt Hotels Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Hyatt Hotels Corporation trades at $189.7 (market cap $17.39B). The key difference: Hyatt Hotels Corporation is far larger — about 2.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | H | |
|---|---|---|
Market Cap | $8.02B | $17.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $202.09 |
52-Week Low | $241.71 | $135.01 |
Enterprise Value | $7.84B | $21.24B |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Hyatt Hotels (H) trades at $184.72, down 3.36% in the last session, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported Q1 2026 EPS of $0.63, beating expectations, but faces profitability challenges with negative net income margins and ROE. Recent developments include expansion announcements and strategic investor presentations, while analyst consensus remains cautiously optimistic with a $198.20 price target.
Hyatt presents a growth opportunity through hotel expansion and premium positioning, but investors face risks from inconsistent profitability, rising debt levels, and economic sensitivity. The stock's valuation appears stretched with a P/E of 31.36, requiring strong execution on revenue growth and margin improvement to justify current levels amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
